Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 23, 2024 3:59pm
147 Views
Post# 35841577

RE:RE:RE:RE:RE:CAR-T update

RE:RE:RE:RE:RE:CAR-T update

Not sure why the name calling.
looser?
in what context?
Admitted trader? Yes in the past 20+ years , I have bought & sold shares of onc.
in the early days. Had a few hundred shares. Sold & never owned until Matt took over from Brad T.
BTW, since 2019 , I have never held zero shares. 
meaning, I have been a continuous  shareholder for 5 years. I buy on dips. Trim a small% on spikes.
Which has not happened since late 2019.
Most importantly, at this point in time I have never held more shares, than now.
The only time I will sell all my shares is when we get final news of buyout or reasonable partership.

so, I guess that qualifies me as a share trader..lol

I put forward mutiple options of what ONC is faced with.
taking the company private is an option with any company @ any time.
Me suggesting that does not mean I want that or even think it would hapoen.
just an opportunity of mutiple options they have.
My preference & suggested best outcome is that of a buyout with Roche.
They are involved with the most trials & positive results. 

I believe in the final outcome & am willing to wait.

Why would Onc mangement take the company private & how..
Same as a buyout. Would require 3rd party auditing, valuations etc.
Chill out & wait.
 

<< Previous
Bullboard Posts
Next >>